This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Good afternoon. Thanks for waiting up; I am Sapna Srivastava; I am Biotech Analyst at Goldman Sachs and it’s my pleasure to host Pat Andrews and Pam Murphy from Incyte. Pat is really responsible as the Chief Commercial Officer and Pam is the Investor Relations entity. So you know we really want to kick this off. I just want to remind the audience that this is meant to be interactive and we want you to ask a lot of questions and keep it as interactive as possible and I am just going to kick it off with like you know really topical and really good news that we saw this morning which is the RA data and while all of us were expecting to see tomorrow, we are really pleased that it came today and we have the opportunity to discuss that at this forum.
So I am going to just start it off with like may be recapping it for the audience who did not necessarily have a chance to see the data and also just to help us understand like how you view the profile of the drug with more visibility on it?